Overview

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Status:
Completed

Trial end date:
2013-09-04

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA 201 IV infusions (1500 mg q8h) versus levofloxacin IV infusions (750 mg qd) for the treatment of adults with a cUTI (including pyelonephritis).

Phase:

Phase 3

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Levofloxacin
Ofloxacin